David A. Ricks
aka Dave Ricks
“Foundayo is a new molecule, a new modality for agonizing GLP-1, and it is a new brand. This is the first time a new incretin medicine has been launched with obesity as its indication first.”
“Pretty much every time we reduce pricing, we see a pretty large expansion [in volume]. In terms of margin sensitivity, the unit economics are really driven by fixed costs that are either sunk in the past or unmovable depending on the volume in the present.”
David A. Ricks
Chairman and CEO of Eli Lilly (LLY). Primary source on GLP-1 market dynamics, Foundayo oral GLP-1 launch, Medicare Bridge, and pricing/volume expansion mechanics.
Said
-
david-ricks in 2026-04-30-earnings-lly-q1-fy2026: "Foundayo is a new molecule, a new modality for agonizing GLP-1, and it is a new brand. This is the first time a new incretin medicine has been launched with obesity as its indication first."
-
david-ricks in 2026-04-30-earnings-lly-q1-fy2026: "Pretty much every time we reduce pricing, we see a pretty large expansion [in volume]... the unit economics are really driven by fixed costs that are either sunk in the past or unmovable depending on the volume in the present."
-
david-ricks in 2026-04-30-earnings-lly-q1-fy2026: "The CMS [Medicare] GLP-1 Bridge... will begin no later than 07/01/2026 and run through December 2027. This program has the potential to help improve the health of millions of seniors while capping their out-of-pocket costs at $50 per month."